MPD: Data set: Wiltshire4

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T. Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmgenomics Pers Med. 2015 Feb 26;8:81-98. doi: 10.2147/PGPM.S73312. eCollection 2015. PubMed 25897258 FullText

Wiltshire4 downloads
• Download Wiltshire4 project data set animal data, as uploaded
• Download Wiltshire4 animal data matrix with factor-related expansion applied as necessary
• Download Wiltshire4 strain means, SD, N, etc. one row per strain/sex/measure
• Wiltshire4 supplementary data

Ontology terms mapped to Wiltshire4 measures:

MA:0000141 spleen
MP:0002458 abnormal B cell number
MP:0006387 abnormal T cell number
MP:0008872 abnormal physiological response to xenobiotic
MP:0012441 abnormal monocyte cell number
VT:0000223 monocyte quantity
VT:0002458 B cell quantity
VT:0006387 T cell quantity
VT:0010487 response to xenobiotic stimulus trait

Investigators	Tim Wiltshire University of North Carolina, Chapel Hill, NC
Participants	Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS
Contact	Tim Wiltshire timw@unc.edu Lab web site
Project type	Phenotype strain survey data set
MPD identifiers	Wiltshire4 MPD:524
Data changelog	No updates/corrections. Initial release date: 01/2016.
Formatted citation	Click above to copy-paste the entire citation for this MPD web page.

The anti-cancer agents studied are: BEZ235, doxorubicin, idarubicin, and selumetinib. Cells were harvested from 4 mice per strain. The investigators normalized the individual animal data such that the controls for each strain / drug / cell analysis group averaged out to 100.0.

Experimental groups in this study:
• BEZ235 • Doxorubicin • Idarubicin • Selumetinib

Procedures conducted:

• immune cell quantification

In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)
Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4:7	Wiltshire4	immune cell quantification	BEZ235	T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4:13	Wiltshire4	immune cell quantification	BEZ235	monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:27	Wiltshire4	immune cell quantification	doxorubicin	T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:41	Wiltshire4	immune cell quantification	idarubicin	B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4

Wiltshire4:61	Wiltshire4	immune cell quantification	selumetinib	B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4:67	Wiltshire4	immune cell quantification	selumetinib	T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4:73	Wiltshire4	immune cell quantification	selumetinib	monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4

Wiltshire4: Toxicity of four anti-cancer agents tested in vitro in immune cells from 36 inbred mouse strains (2015)